Table 6.
Effects of INSTI-Based Regimens on BMI, Waist Circumference, Fasting Glucose, LDL-C, Metabolic Syndrome, and Hypertension, With and Without Participants on TAF-Based Regimensa
| Outcome | Effects of INSTI-Based Regimens With TAF Users | Effects of INSTI-Based Regimens Without TAF Users | ||
|---|---|---|---|---|
| Crude Estimate (95% CI) | Weighted Estimate (95% CI)b | Crude Estimate (95% CI) | Weighted Estimate (95% CI)b | |
| Linear Regressionsc | ||||
| BMI (kg/m2) | 1.3 (1.0–1.7) | 1.5 (1.0–1.9) | 1.1 (0.8–1.5) | 1.4 (0.9–1.9) |
| Waist circumference (cm) | 3.8 (2.9–4.6) | 3.6 (2.6–4.6) | 3.3 (2.3–4.2) | 3.4 (2.2–4.5) |
| Fasting glucose (mg/dL) | 0.9 (−0.7 to 1.0) | −0.02 (−1.0 to 0.9) | 0.2 (−0.7 to 1.2) | −0.01 (−1.0 to 1.0) |
| Fasting LDL (mg/dL) | −0.5 (−2.3 to 1.4) | −0.9 (−3.0 to 1.3) | −2.5 (0.02) | −1.6 (−4.0 to 0.7) |
| Logistic Regressionsd | ||||
| Crude OR (95% CI) | Weighted OR (95% CI) | Crude OR (95% CI) | Weighted OR (95% CI) | |
| Obesity | 1.5 (1.3–1.4) | 1.6 (1.4–1.9) | 1.4 (1.2–1.7) | 1.6 (1.3–1.9) |
| Metabolic syndrome | 0.9 (0.8–1.0) | 0.9 (0.8–1.1) | 0.9 (0.8–1.0) | 0.9 (0.8–1.1) |
| Hypertension | 1.1 (1.0–1.3) | 1.1 (1.0–1.3) | 1.1 (1.0–1.3) | 1.2 (1.0–1.4) |
Abbreviations: BMI, body mass index; CI, confidence interval; INSTI, integrase-strand transfer inhibitor; LDL-C, low-density lipoprotein cholesterol; OR, odds ratio; TAF, tenofovir alafenamide.
Weighted estimates are estimated using inverse probability of treatment weights (IPTW).
Covariates used to create IPTW included the following: natal sex, age, race, CD4 count, estimated glomerular filtration rate (</>90), smoking status, substance use, estrogen-containing preparations, testosterone-containing preparations, diet quality, and physical activity level. Sex-stratified regressions used re-estimated IPTW excluding natal sex.
Estimates represent absolute difference (INSTI use vs no INSTI use).
Estimates represent odds ratios (INSTI use vs no INSTI use).